Synopsis

Source of validity: Scientific
Rating (out of 5): 4

Nitric oxide (NO) is scientifically validated as having a role in the management of thrombosis, primarily due to its vasodilatory and antiplatelet effects. Nitric oxide is a key endogenous molecule produced by endothelial cells lining blood vessels. It inhibits platelet aggregation and adhesion by increasing cyclic GMP within platelets, thus reducing their activation and the risk of thrombus (clot) formation. Moreover, NO causes vasodilation, which helps maintain blood flow and further decreases the likelihood of clot development.

Clinical and experimental studies have shown that impaired NO bioavailability is associated with an increased risk of thrombosis and atherosclerosis. Therapeutic interventions that enhance NO signaling—such as NO donors or phosphodiesterase inhibitors—have been investigated in both preclinical and clinical settings to prevent and treat thrombotic events. For example, inhaled nitric oxide is sometimes used in specific clinical situations to manage pulmonary hypertension and related thrombotic complications.

While NO-based therapies are not the frontline treatment for thrombosis (anticoagulants and antiplatelet agents remain primary), there is strong mechanistic and translational evidence supporting its adjunctive role. The evidence is rated at 4, as there are both robust mechanistic data and some clinical application, but NO is not yet a standard, standalone therapy for venous or arterial thrombosis.

More about Nitric Oxide
More about Thrombosis

Other ingredients used for Thrombosis

Other health conditions supported by Nitric Oxide

Products containing Nitric Oxide